MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arbutus Biopharma Corp

Closed

3.12 -0.32

Overview

Share price change

24h

Current

Min

3.08

Max

3.16

Key metrics

By Trading Economics

Income

-12M

-25M

Sales

190K

1.8M

Profit margin

-1,390.363

Employees

44

EBITDA

-12M

-24M

Dividends

By Dow Jones

Next Earnings

31 lip 2025

Market Stats

By TradingEconomics

Market Cap

-21M

621M

Previous open

3.44

Previous close

3.12

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Arbutus Biopharma Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 lip 2025, 21:01 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 20:50 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 20:46 UTC

Earnings

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 lip 2025, 20:39 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 20:36 UTC

Earnings

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 lip 2025, 20:16 UTC

Acquisitions, Mergers, Takeovers

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 lip 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 lip 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 lip 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 lip 2025, 18:24 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 lip 2025, 18:19 UTC

Earnings

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 lip 2025, 18:11 UTC

Acquisitions, Mergers, Takeovers

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 lip 2025, 18:11 UTC

Earnings

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 lip 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 lip 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 lip 2025, 16:28 UTC

Acquisitions, Mergers, Takeovers

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 lip 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

18 lip 2025, 16:20 UTC

Market Talk
Earnings

Basic Materials Roundup: Market Talk

18 lip 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 lip 2025, 16:04 UTC

Earnings

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 lip 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 lip 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 lip 2025, 15:47 UTC

Market Talk
Earnings

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Peer Comparison

Price change

Arbutus Biopharma Corp Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

3.255 / 3.365Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.